The global drugs for vancomycin resistant enterococcus faecium market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Amongst the variety of microbial flora present in human body, Staphylococcus aureus, a gram-positive bacterium, is mostly found on the skin as well as nasal passages of humans. According to the United States Department of Health (USDoH), 20% of the global population is always colonized with Staphylococcus aureus. Being a facultative anaerobe, it can cause respiratory diseases, skin illness, and food poisoning. According to the Health Research Funding Organization, nearly 19,000 mortalities are registered globally due to Staph infection every year. According to Centre of Disease Control and Prevention (CDC), there were 13 cases in 4 states of US, during 2002-2013. In due course of time, the species of Staphylococcus aureus have developed resistance to many of the antimicrobial drugs. For instance, MRSA, a class of Staphylococcus aureus which is resistant to Methicillin.

Other than the majorly known Staph infection, it is also the common contributing agent for illnesses such as boils, impetigo, pimples, abscesses, and certain serious diseases such as pneumonia, meningitis, osteomyelitis, sepsis, and others. Thus, to treat such illnesses, the demand for drugs for vancomycin resistant enterococcus faecium is likely to grow during the forecast period. As per the National Center for Biotechnology Information (NCBI), two novel antimicrobial agents that include quinupristin/ dalfopristin, and linezolid, have emerged as approved therapeutic options for vancomycin-resistant Enterococcus faecium on the basis of in vitro susceptibility and clinical efficacy from multicentre, pharmaceutical company-sponsored clinical trials.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application  

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Aphios Corp., and Pfizer Inc., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Drugs for Vancomycin Resistant Enterococcus Faecium Market Report by Segment

By Type

• Daptomycin 

• Linezolid

• Quinupristin/Dalfopristin

• Ampicillin

• Chloramphenicol

• Others

By Application

• Hospital

• Clinic

• Others

Global Drugs for Vancomycin Resistant Enterococcus Faecium Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa